The role of inter-segmental differences in P-glycoprotein expression and activity along the rat small intestine in causing the double-peak phenomenon of substrate plasma concentration

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2013, Pages 98-103

  Wada, Sho ^a   Kano, Takashi ^a   Mita, Suzune ^a   Idota, Yoko ^a   Morimoto, Kaori ^a   Fumiyoshi, Yamashita ^b   Takuo, Ogihara ^a  

^a TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Compartment model; Permeability glycoprotein (P gp); Plasma double peak phenomenon; Rhodamine123; Small intestine

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DUODENUM; EXCRETION; ILEUM; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SMALL INTESTINE;

EID: 84876766841     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-005     Document Type: Article

References (46)

1. Arceci, R. J.: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81: 2215-2222 (1993).
2. Holmes, J. A. and West, R. R.: The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. Br. J. Cancer, 69: 382-384 (1994).
3. Juranka, P. F., Zastawny, R. L. and Ling, V.: P-glycoprotein: multidrug resistance and a superfamily of membrane-associated transport proteins. FASEB J., 3: 2583-2592 (1989).
4. Nooter, K. and Herweijer, H.: Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer, 63: 663-669 (1991).
5. Bello-Reuss, E., Ernest, S., Holland, O. B. and Hellmich, M. R.: Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am. J. Physiol. Cell Physiol., 278: C1256-C1265 (2000).
6. Tanigawara, Y.: Role of P-glycoprotein in drug disposition. Ther. Drug Monit., 22: 137-140 (2000).
7. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. and Bertino, J. R.: Multidrug-resistance gene (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA, 86: 695-698 (1989).
8. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J. and Yang, C. P. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15: 55-61 (1993).
9. Petri, N., Bergman, E., Forsell, P., Hedeland, M., Bondesson, U., Knutson, L. and Lennernäs, H.: First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab. Dispos., 34: 1182-1189 (2006).
10. Morimoto, K., Nakakariya, M., Shirasaka, Y., Kakinuma, C., Fujita, T., Tamai, I. and Ogihara, T.: Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab. Dispos., 36: 6-9 (2008).
11. Ose, A., Kusuhara, H., Yamatsugu, K., Kanai, M., Shibasaki, M., Fujita, T., Yamamoto, A. and Sugiyama, Y.: P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab. Dispos., 36: 427-434 (2008).
12. Mizuno, N., Niwa, T., Yotsumoto, Y. and Sugiyama, Y.: Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev., 55: 425-461 (2003).
13. Prashanth, S., Kumar, A. A., Madhu, B., Rama, N. and Sagar, J. V.:Pharmacokinetic and pharmacodynamic drug interactions of carbamazepine and glibenclamide in healthy albino Wistar rats. J. Pharmacol. Pharmacother., 2: 7-10 (2011).
14. Marchetti, S., de Vries, N. A., Buckle, T., Bolijn, M. J., van Eijndhoven M. A., Beijnen, J. H., Mazzanti, R., van Tellingen, O. and Schellens, J. H.: Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp11/1/Mdr1a/1b1/1 (tripleknockout) and wild-type mice. Mol. Cancer Ther., 7: 2280-2287 (2008).
15. Soo, G. W., Law, J. H., Kan, E., Tan, S. Y., Lim, W. Y., Chay, G., Bukhari, N. I. and Segarra, I.: Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. Anticancer Drugs, 21: 695-703 (2010).
16. Kruijtzer, C. M. F., Beijnen, J. H. and Schellens, J. H. M.: Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist, 7: 516-530 (2002).
17. Ogihara, T., Kamiya, M., Ozawa, M., Fujita, T., Yamamoto, A., Yamashita, S., Ohnishi, S. and Isomura, Y.: What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab. Pharmacokinet., 21: 238-244 (2006).
18. Makhey, V. D., Guo, A., Norris, D. A., Hu, P., Yan, J. and Sinko, P. J.: Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res., 15: 1160-1167 (1998).
19. Yumoto, R., Murakami, T., Nakamoto, Y., Hasegawa, R., Nagai, J. and Takano, M.: Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Exp. Ther., 289: 149-155 (1999).
20. Stephens, R. H., Tanianis-Hughes, J., Higgs, N. B., Humphrey, M. and Warhurst, G.: Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(1/1) mouse intestine. J. Pharmacol. Exp. Ther., 303: 1095-1101 (2002).
21. Ho, G. T., Moodie, F. M. and Satsangi, J.: Multidrug resistance 1 gene (Pglycoprotein 170): an important determinant in gastrointestinal disease? Gut, 52: 759-766 (2003).
22. Lin, Y., Shen, Q., Katsumi, H., Okada, N., Fujita, T., Jiang, X. and Yamamoto, A.: Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a Pglycoprotein substrate, in rats. Biol. Pharm. Bull., 30: 1301-1307 (2007).
23. Mouly, S. and Paine, M. F.: P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res., 20: 1595-1599 (2003).
24. Fricker, G., Drewe, J., Huwyler, J., Gutmann, H. and Beglinger, C.: Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol., 118: 1841-1847 (1996).
25. Jin, M., Shimada, T., Yokogawa, K., Nomura, M., Ishizaki, J., Piao, Y., Kato, Y., Tsuji, A. and Miyamoto, K.: Site-dependent contributions of Pglycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Biochem. Pharmacol., vol72/vol: 1042-1050 (date2006/date).
26. Furihata, T., Satoh, N., Ohishi, T., Ugajin, M., Kameyama, Y., Morimoto, K., Matsumoto, S., Yamashita, K., Kobayashi, K. and Chiba, K.: Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J., 9: 185-193 (2009).
27. Kadono, K., Yokoe, J., Ogawara, K., Higaki, K. and Kimura, T.: Analysis and prediction of absorption behavior for theophylline orally administered as powders based on gastrointestinal-transit-absorption (gita) model. Drug Metab. Pharmacokinet., 17: 307-315 (2002).
28. Berggren, S., Gall, C., Wollnitz, N., Ekelund, M., Karlbom, U., Hoogstraate, J., Schrenk, D. and Lennernäs, H.: Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm., 4: 252-257 (2007).
29. Kagan, L., Dreifinger, T., Mager, D. E. and Hoffman, A.: Role of pglycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab. Dispos., 38: 1560-1566 (2010).
30. Gao, W., Kageyama, M., Inoue, Y., Tadano, J., Fukumoto, K., Fukushima, K., Yamasaki, D., Nishimura, A., Yoshikawa, Y., Shibata, N. and Takada, K.: Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats. Biol. Pharm. Bull., 26: 199-204 (2003).
31. Kageyama, M., Fukushima, K., Togawa, T., Fujimoto, K., Taki, M., Nishimura, A., Ito, Y., Sugioka, N., Shibata, N. and Takada, K.: Relationship between excretion clearance of rhodamine 123 and Pglycoprotein (Pgp) expression induced by representative Pgp inducers. Biol. Pharm. Bull., 29: 779-784 (2006).
32. Kageyama, M., Namiki, H., Fukushima, H., Ito, Y., Shibata, N. and Takada, K.: In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for Pglycoprotein and cytochrome P450 (CYP) 3A in rats. Biol. Pharm. Bull., 28: 316-322 (2005).
33. Langguth, P., Lee, K. M., Spahn-Langguth, H. and Amidon, G. L.: Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm. Drug Dispos., 15: 719-746 (1994).
34. Mummaneni, V., Amidon, G. L. and Dressman, J. B.: Gastric pH influences the appearance of double-peaks in the plasma concentrationtime profiles of cimetidine after oral administration in dogs. Pharm. Res., 12: 780-786 (1995).
35. Piyapolrungroj, N., Zhou, Y. S., Li, C., Liu, G., Zimmermann, E. and Fleisher, D.: Cimetidine absorption and elimination in rat small intestine. Drug Metab. Dispos., 28: 65-72 (2000).
36. Ogiso, T., Kasutani, M., Tanaka, H., Iwaki, M. and Tanino, T.: Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. Biol. Pharm. Bull., 24: 790-794 (2001).
37. 14C-polyethylene glycol (PEG) 4000. Pharm. Res., 10: 130-135 (1993).
38. Lennernäs, H. and Regårdh, C. G.: Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile Pharm. Res., 10: 879-883 (1993).
39. Wu, W., Wang, Y. and Que, L.: Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm., 63: 288-294 (2006).
40. Orlando, R., Sawadogo, A., Miglioli, P. A., Cappellazzo, M. G. and Palatini, P.: Oral disposition kinetics of ofloxacin in patients with compensated liver cirrhosis. Chemotherapy, 38: 1-6 (1992).
41. Vinge, E., Andersson, K. E., Ando, G. and Lunell, E.: Biological availability and pharmacokinetics of tinidazole after single and repeated doses. Scand. J. Infect. Dis., 15: 391-397 (1983).
42. Lehr, T., Staab, A., Tillmann, C., Trommeshauser, D., Schaefer, H. G. and Kloft, C.: A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin. Pharmacokinet., 48: 529-542 (2009).
43. Orlando, R., Sawadogo, A., Miglioli, P. A., Cappellazzo, M. G. and Palatini, P.: Oral disposition kinetics of ofloxacin in patients with compensated liver cirrhosis. Chemotherapy, 38: 1-6 (1992).
44. Amiodarone Hydrochloride: Interview form; Standard Commodity Classification for Japan; 872129, Sawai Pharmaceutical Co. Ltd. (2011)
45. Fexofenadine Hydrochloride: Interview form; Standard Commodity Classification for Japan; 87449, Sanofi-Aventis Co. Ltd. (2011)
46. Morimoto, K., Kishimura, K., Nagami, T., Kodama, N., Ogama, Y., Yokoyama, M., Toda, S., Chiyoda, T., Shimada, R., Inano, A., Kano, T., Tamai, I. and Ogihara, T.: Effect of milk on the pharmacokinetics of oseltamivir in Healthy volunteers. J. Pharm. Sci., 100: 3854-3861 (2011).